Buying shares of early stage biotech companies is one of the ways that cash-strapped investors can plant the seeds of massive growth. And, with enough luck, someday those nascent businesses might grow to become formidable companies with budding rosters of life-saving drugs.
Citius Pharmaceuticals (NASDAQ: CTXR) is typical of such a small biotech: It doesn't have any revenue or profits, and its only hope of getting either is to follow through on its drugs in development. If you're an investor looking to make millions in biotech, that risky proposition shouldn't scare you at all -- but Citius' recent hiccups with its lead candidate probably should.
Image source: Getty Images.
For further details see:
Could Citius Pharmaceuticals Be a Millionaire-Maker Stock?